SAB Biotherapeutics, Inc., was incorporated in Delaware on November 12, 2020. The company is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapy antibodies (human immunoglobulin G, HIGG) for the treatment of immunological disorders. The company's pipeline projects have achieved proof-of-concept in clinical trials for indications with significant unmet medical needs, and product candidates target diseases including type 1 diabetes (T1D) and other autoimmune diseases. The antibodies found inside are both target-specific and polyclonal. They are composed of multiple HIGGs and can bind to multiple sites on targeted immunogens, making them ideal for solving complex immune-mediated diseases. The company's proprietary platform can generate more new therapeutic candidates to expand its pipeline, leveraging the human immune response to generate the best library of HIGG for drug targets of interest.